Dangerous infectious diseases: Bad news for Main Street, good news for Wall Street?

Abstract

a b s t r a c tWe examine whether investor mood, driven by World Health Organization (WHO) alerts and media news on dangerous infectious diseases, is priced in pharmaceutical companies' stocks in the United States. We argue that disease-related news (DRNs) should not trigger rational trading. We find that DRNs have a positive and significant sentiment effect among investors (on Wall Street). The effect is stronger (weaker) for small (large) companies, who are less (more) likely to engage in the development of new vaccines. A potential negative investor climate (on Main Street)induced by disease-related feardoes not alter the positive sentiment effect.

Stock Market Efficiency in the Time of COVID-19: Evidence from Industry Stock Returns

“…is such that it will affect some sectors more than others. Donadelli, Kizys, and Riedel (2017) also report that the news of infectious diseases has sectoral implications. Second, the selection of industry portfolios reduces the influence of stocks' idiosyncratic risk on the test results.…”

The COVID-19 Outbreak and Affected Countries Stock Markets Response

“…Events like infectious disease outbreaks can induce negative changes in investors' sentiment that strongly affects their investment decisions and, consequently, stock market prices. In countries that are culturally more susceptible to herd-like actions and overreaction or countries with low institutional participation, the effect of investor sentiment on stock markets is more pronounced [29,30].…”

This time is indeed different: A study on global market reactions to public health crisis

“…Our research is related to the literature on economic impacts of pandemics. Donadelli et al (2017) documented that investor ✩ This paper is partly based on Daniel Schell's bachelor thesis titled ''Public health risk announcements and stock market reaction'' at the WHU -Otto Beisheim School of Management Germany. mood, driven by WHO alerts and disease-related news, leads to a significant positive effect on pharmaceutical companies' stock returns in the United States.…”